Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Operating Cash Flow Per Share for the quarter ending September 30, 2023: -1.99

Freeline Therapeutics Holdings Plc Operating Cash Flow Per Share is -1.99 for the quarter ending September 30, 2023, a 43.17% change year over year. Operating cash flow per share represents the amount of cash generated from a company's core operations per outstanding share. It is calculated by dividing the operating cash flow by the weighted average number of basic shares outstanding. This metric provides insights into the company's ability to generate cash flow from its day-to-day operations on a per-share basis. It is useful for evaluating the company's cash flow generation and comparing it with other companies on a per-share basis.
  • Freeline Therapeutics Holdings Plc Operating Cash Flow Per Share for the quarter ending September 30, 2022 was -3.50, a 63.23% change year over year.
  • Freeline Therapeutics Holdings Plc Operating Cash Flow Per Share for the quarter ending September 30, 2021 was -9.52, a 28.79% change year over year.
  • Freeline Therapeutics Holdings Plc Operating Cash Flow Per Share for the quarter ending September 30, 2020 was -13.38, a -2,083.42% change year over year.
  • Freeline Therapeutics Holdings Plc Operating Cash Flow Per Share for the quarter ending March 31, 2019 was -0.61, a -103.01% change year over year.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email